Scientific Advisory Board
Friends of FSH Research manages a portfolio of grants to accelerate discoveries for FSHD. To do this, we leverage the expertise of our world-class scientific advisory board.
Our Board members are bound by a set of Covenants. Please do not hesitate to contact us to learn more about how we review our science, and maintain an active an collaborative culture to ensure robust and reproducible findings.
Dr. Arjomand is a neuroscientist and molecular biologist with 20+ years of industry experience, including directing R&D programs using a virtual pharma model through collaboration with academia, contract research organizations and biotech companies.
Dr. Bennett is head of the Gene Therapy Unit at Novartis, with more than a decade experience in R&D.
Dr. Block is CEO, Co-Founder, & Board Chair at Histone Therapeutics.
Dr. Chamberlain is a Professor of Neurogenetics, Biochemistry, and Medical Genetics, University of Washington. He also chairs our Scientific Advisory Board.
Dr. Premi Haynes is a Senior Scientist at Bristol Myers Squibb located in Seattle, WA.
Dr. Van der Maarel is a Professor of Medical Epigenetics at Leiden University Medical Center in The Netherlands.
Amanda Rickard is a scientist in Epigenetics at Pfizer Oncology in San Diego and Friends of FSH Research Board of Directors member.
Dr. Shaw is Division Chief of MRI and Vascular/Interventional Imaging at Seattle Children's Hospital.
Assistant professor of neurology at the University of Kansas Medical Center with both clinical and research training in neuromuscular diseases.
Dr. Wentworth is the Senior Scientific Advisor at Dyne Therapeutics.
Dr. Yokomori is a Professor, Biological Chemistry School of Medicine, University of California at Irvine.
Connect with us on social media